Why Supernus Pharmaceuticals Plunged 15% Today [The Motley Fool]
Supernus Pharmaceuticals, Inc. (SUPN)
Last supernus pharmaceuticals, inc. earnings: 2/25 04:40 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.supernus.com
Company Research
Source: The Motley Fool
Why Supernus Pharmaceuticals Plunged 15% Today Shares slumped after the commercial-stage biopharma reported mixed results. In response to the company announcing mixed fourth-quarter results and issuing weak guidance, shares of Supernus Pharmaceuticals ( NASDAQ:SUPN ) , a biopharma focused on diseases of the central nervous system , slumped 15% on Wednesday. The headline numbers for the quarter were mixed: In other news, the FDA has accepted Supernus' New Drug Application for SPN-812 as a potential treatment for ADHD. A target action date of Nov. 8, 2020, has been set. The company plans to launch the drug in the fourth quarter of 2020 if everything goes according to plan. Meanwhile, management decided to halt all development activities of a compound called SPN-810 after the drug failed to produce the desired result in a phase 3 trial. Supernus CEO Jack Khattar commented: For 2020, management believes that net product sales will range between $360 million and $390 million. The midpoint
Show less
Read more
Impact Snapshot
Event Time:
SUPN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SUPN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SUPN alerts
High impacting Supernus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SUPN
News
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPNGlobeNewswire
- Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of InvestorsBusiness Wire
- INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of InvestorsBusiness Wire
- Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story [Yahoo! Finance]Yahoo! Finance
- Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree StoryGlobeNewswire
SUPN
Earnings
- 2/27/24 - Miss
SUPN
Sec Filings
- 4/29/24 - Form DEFA14A
- 4/29/24 - Form ARS
- 4/29/24 - Form DEF
- SUPN's page on the SEC website